Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL, INCCOLL · Entity 5169 | Director | November 12, 2025 | November 14, 2025 |
| EXACT SCIENCES CORPEXAS · Entity 56619 | Director | July 30, 2018 | August 01, 2018 |
| INSULET CORPPODD · Entity 3516 | Director | May 21, 2021 | May 25, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
COLLEGIUM PHARMACEUTICAL, INC
Report date November 12, 2025 · Filed November 14, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 64,634 |
Ending reported balance
After 2025-11-12 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2025-11-12 · Exercise / conversion · Acquired 15,000 · Balance 79,634 Row 2 · 2025-11-12 · Exercise / conversion · Acquired 19,853 · Balance 99,487 Row 3 · 2025-11-12 · Sale · Disposed 34,853 · Balance 64,634 F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $16.49 · Expires 2026-06-09 | Direct | 0 |
Reported balance
After 2025-11-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-11-12 · Exercise / conversion · Disposed 15,000 · Balance 0 F2: The option is fully vested and exercisable. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $9.33 · Expires 2027-05-24 | Direct | 0 |
Reported balance
After 2025-11-12 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-11-12 · Exercise / conversion · Disposed 19,853 · Balance 0 F2: The option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2: The option is fully vested and exercisable.
EXACT SCIENCES CORP
Report date July 30, 2018 · Filed August 01, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 33,767 |
Reported balance
After 2018-07-30 transaction · row 1
1 source rowRow 1 · 2018-07-30 · Sale · Disposed 2,373 · Balance 33,767 F1: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Column 4 were effected pursuant to a Rule 10b5-1 Trading Plan adopted by the reporting person to cover tax liabilities arising out of the vesting of shares of restricted stock.
INSULET CORP
Report date May 21, 2021 · Filed May 25, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,498 |
Ending reported balance
After 2021-05-21 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2021-05-21 · Exercise / conversion · Acquired 2,235 · Balance 16,733 Row 2 · 2021-05-21 · Exercise / conversion · Acquired 3,587 · Balance 20,320 Row 3 · 2021-05-21 · Sale · Disposed 2,235 · Balance 18,085 Row 4 · 2021-05-21 · Sale · Disposed 3,587 · Balance 14,498 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.87 · Expires 2026-05-11 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-05-21 · Exercise / conversion · Disposed 2,235 · Balance 0 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $40.60 · Expires 2027-05-17 | Direct | 0 |
Reported balance
After 2021-05-21 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-05-21 · Exercise / conversion · Disposed 3,587 · Balance 0 |
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
AMAG PHARMACEUTICALS, INC.
Report date November 16, 2020 · Filed November 17, 2020
Section 16 reporting ended · disclosed 2020-11-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 1
1 source rowRow 1 · 2020-11-16 · Disposition to issuer · Disposed 37,362 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-11-16 · Disposition to issuer · Disposed 6,000 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-11-16 · Disposition to issuer · Disposed 2,534 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-11-16 · Disposition to issuer · Disposed 3,575 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-11-16 · Disposition to issuer · Disposed 12,787 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-11-16 · Disposition to issuer · Disposed 10,110 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2020-11-16 · Disposition to issuer · Disposed 7,543 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2020-11-16 · Disposition to issuer · Disposed 17,326 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-11-16 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2020-11-16 · Disposition to issuer · Disposed 21,289 · Balance 0 F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes.
F2: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration.
F3: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 12, 2025 Filed Nov 14, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 19,853 | $0.00 Strike: $9.33 | $0.00 |
DisclosureSEC source: 0001560152-25-000004 · form4-11142025_091156.xml · derivative · entry 5 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,853 shares Expires 2027-05-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionStock Option (Right to Purchase) · Derivative | 15,000 | $0.00 Strike: $16.49 | $0.00 |
DisclosureSEC source: 0001560152-25-000004 · form4-11142025_091156.xml · derivative · entry 4 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option is fully vested and exercisable. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | SaleCommon Stock | 34,853 | $47.21 | $1,645,535.60 |
DisclosureSEC source: 0001560152-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,634 F1 · price: The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $46.805 to $47.51, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 19,853 | $9.33 | $185,228.49 |
DisclosureSEC source: 0001560152-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,487 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 12, 2025 Filed Nov 14, 2025 21:10 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | Exercise / conversionCommon Stock | 15,000 | $16.49 | $247,350.00 |
DisclosureSEC source: 0001560152-25-000004 · form4-11142025_091156.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 79,634 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 15, 2025 Filed May 19, 2025 21:43 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,791 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-009810 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,634 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| May 16, 2024 Filed May 16, 2024 23:22 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 7,693 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-010539 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,843 F1 · shares: Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs vest on May 16, 2025, subject to the director's continued service with the Issuer. The RSUs will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the Issuer, in shares of the Issuer's common stock. Read SEC document |
| May 18, 2023 Filed May 19, 2023 20:39 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,792 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-011816 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,150 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 18, 2024, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 19, 2022 Filed May 23, 2022 20:43 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 14,035 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-013301 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,358 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 19, 2023, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:51 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,587 | $0.00 Strike: $40.60 | $0.00 |
DisclosureSEC source: 0001127602-21-018010 · form4.xml · derivative · entry 6 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,587 shares Expires 2027-05-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:51 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,235 | $0.00 Strike: $28.87 | $0.00 |
DisclosureSEC source: 0001127602-21-018010 · form4.xml · derivative · entry 5 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,235 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:51 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 3,587 | $253.21 | $908,246.34 |
DisclosureSEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 4 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,498 Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:51 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 2,235 | $253.61 | $566,808.29 |
DisclosureSEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,085 Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:51 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 3,587 | $40.60 | $145,632.20 |
DisclosureSEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 21, 2021 Filed May 25, 2021 20:51 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 2,235 | $28.87 | $64,524.45 |
DisclosureSEC source: 0001127602-21-018010 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,733 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 20, 2021 Filed May 24, 2021 21:20 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 9,941 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-21-000457 · edgar.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,323 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2022, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 21,289 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 9 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 21,289 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,326 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 8 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,326 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 7,543 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 7 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,543 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 6 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,110 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 12,787 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 5 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,787 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 3,575 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 4 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,575 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 2,534 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,534 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerStock Option (Right to Buy) · Derivative | 6,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,000 shares Expires not disclosed F3 · derivative.exercise_price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · price: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.exercise_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. F3 · derivative.expiration_date: Immediately prior to the Effective Time, each Company option that was outstanding (whether vested or unvested) and then exercisable for a per share exercise price less than the Merger Consideration that would be payable in respect of the Shares underlying such Company option (any such Company option, an "In-the-Money Cash Out Option") was cancelled and automatically converted into the right to receive for each Share underlying such Company option, without interest and subject to deduction for any required withholding under applicable tax law, an amount in cash from Parent or the Issuer equal to the excess of the Merger Consideration over the per share exercise price of such Company option. All Company options that were not In-the-Money Cash Out Options were cancelled at the Effective Time without payment of any consideration. Read SEC document |
| November 16, 2020 Filed Nov 17, 2020 15:41 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | Disposition to issuerCommon Stock | 37,362 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-126318 · a4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · shares: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 1, 2020, by and among the Issuer, Covis Group S.a.r.l. ("Parent"), and Covis Mergerco Inc., a direct wholly owned subsidiary of Parent ("Merger Sub"), and (in respect of specific matters) Covis Finco S.a r.l., pursuant to which Merger Sub merged with and into the Issuer (the "Merger") effective as of November 16, 2020 (the "Effective Time"). Immediately prior to the Effective Time, each issued and outstanding share of common stock of the Issuer (each, a "Share") was cancelled and converted into the right to receive $13.75 in cash (the "Merger Consideration") without interest and subject to applicable withholding taxes. F2 · price: A portion of this amount consists of unvested restricted stock units ("RSUs"). Each Company RSU that is outstanding immediately prior to the Effective Time, whether vested or unvested, was cancelled and automatically converted into the right to receive for each Share underlying such RSU, without interest and subject to deduction for any required withholding taxes, an amount in cash from Parent or the Issuer equal to the Merger Consideration. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:05 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $28.87 | $0.00 |
DisclosureSEC source: 0001127602-20-028354 · form4.xml · derivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,235 Underlying: Common Stock · 3,000 shares Expires 2026-05-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:05 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 3,000 | $230.00 | $690,000.00 |
DisclosureSEC source: 0001127602-20-028354 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,498 F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| November 04, 2020 Filed Nov 6, 2020 21:05 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 3,000 | $28.87 | $86,610.00 |
DisclosureSEC source: 0001127602-20-028354 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $35.11 | $0.00 |
DisclosureSEC source: 0001127602-20-027995 · form4.xml · derivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2024-06-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on April 30, 2015, 25% of the total award vesting on April 30, 2016 and 25% of the total award vesting on April 30, 2017, subject to continued service as a director or consultant. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 4,000 | $225.00 | $900,000.00 |
DisclosureSEC source: 0001127602-20-027995 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,498 F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| November 02, 2020 Filed Nov 3, 2020 21:05 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 4,000 | $35.11 | $140,440.00 |
DisclosureSEC source: 0001127602-20-027995 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,498 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The transactions reported in this Form 4 were effected pursuant to an existing Rule 10b5-1 trading plan. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 21,289 | Not disclosed Strike: $8.52 | Not disclosed |
DisclosureSEC source: 0000792977-20-000060 · wf-form4_159130377601364.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,289 Underlying: Common Stock · 21,289 shares Expires 2030-06-02 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders. Read SEC document |
| June 02, 2020 Filed Jun 4, 2020 16:49 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 10,269 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-20-000060 · wf-form4_159130377601364.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,362 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2020 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| May 28, 2020 Filed Jun 1, 2020 20:57 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-018247 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,498 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2021 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:23 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 8,095 | $0.00 Strike: $22.05 | $0.00 |
DisclosureSEC source: 0001192482-20-000364 · edgar.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,095 Underlying: Common Stock · 8,095 shares Expires 2030-05-20 F2 · derivative.exercise_date: The option vests and becomes exercisable on May 20, 2021, subject to the director's continued service with the issuer. Read SEC document |
| May 20, 2020 Filed May 22, 2020 20:23 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,047 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-20-000364 · edgar.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,382 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on May 20, 2021, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,000 | $0.00 Strike: $30.04 | $0.00 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · derivative · entry 8 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires 2023-06-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is subject to the following vesting schedule: 50% of the total award shall vest on April 30, 2014, 25% of the total award shall vest on April 30, 2015 and 25% of the total award shall vest on April 30, 2016, subject to continued service as a director or consultant. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,525 | $0.00 Strike: $27.37 | $0.00 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · derivative · entry 7 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,525 shares Expires 2025-05-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on April 30, 2016, 25% of the total award vesting on April 30, 2017 and 25% of the total award vesting on April 30, 2018, subject to continued service as a director or consultant. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 9,525 | $181.41 | $1,727,917.87 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 5 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,469 F1 · price: The price reported represents the weighted average sale price of the shares sold. The shares were sold at varying prices in the range of $181.18 to $182.82. The Reporting Person hereby undertakes, upon request of the Staff of the U.S. Securities Exchange Commission, the Issuer or a security holder of the Issuer, to provide full information regarding the number of shares sold at each separate price. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 4,000 | $30.04 | $120,160.00 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 4 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 18, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,525 | $27.37 | $151,219.25 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,994 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · derivative · entry 6 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | SaleCommon Stock | 5,000 | $180.07 | $900,325.00 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,469 Read SEC document |
| November 15, 2019 Filed Nov 19, 2019 21:08 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionCommon Stock | 5,000 | $21.35 | $106,750.00 |
DisclosureSEC source: 0001127602-19-033198 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,469 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 30, 2019 Filed Jun 3, 2019 21:37 UTC | INSULET CORP PODD · Entity 3516 | GrantCommon Stock | 1,726 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-020531 · form4.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,469 F1 · shares: Annual equity award in the form of restricted stock units ("RSUs"). RSUs vest in full on April 30, 2020 and are settled in shares of common stock on a one-for-one basis. Read SEC document |
| May 16, 2019 Filed May 20, 2019 07:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantStock Option (Right to Buy) · Derivative | 17,326 | Not disclosed Strike: $10.78 | Not disclosed |
DisclosureSEC source: 0000792977-19-000104 · wf-form4_155835163385617.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,326 Underlying: Common Stock · 17,326 shares Expires 2029-05-16 F2 · price: Not applicable. F3 · derivative.exercise_date: Grant of stock option pursuant to the Plan. This option will vest and become exercisable in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders. Read SEC document |
| May 16, 2019 Filed May 20, 2019 07:27 UTC | AMAG PHARMACEUTICALS, INC. AMAG · Entity 145305 | GrantCommon Stock | 8,116 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000792977-19-000104 · wf-form4_155835163385617.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,093 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of Common Stock of AMAG Pharmaceuticals, Inc. (the "Issuer"). These shares of Common Stock are issuable pursuant to a grant of restricted stock units pursuant to the Issuer's 2019 Equity Incentive Plan (the "Plan") that will vest in twelve equal monthly installments over one year beginning on the first day of the first full month following the Issuer's 2019 annual meeting of stockholders; however, delivery of the shares is deferred until the earlier of (a) one year from the date of grant and (b) the date of the director's separation from service to the Issuer. F2 · price: Not applicable. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:55 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantStock Option (Right to Purchase) · Derivative | 9,414 | $0.00 Strike: $14.57 | $0.00 |
DisclosureSEC source: 0001192482-19-000222 · edgar.xml · derivative · entry 2 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,414 Underlying: Common Stock · 9,414 shares Expires 2029-04-25 F2 · derivative.exercise_date: The option vests and becomes exercisable on April 25, 2020, subject to the director's continued service with the issuer. Read SEC document |
| April 25, 2019 Filed Apr 29, 2019 22:55 UTC | COLLEGIUM PHARMACEUTICAL, INC COLL · Entity 5169 | GrantCommon Stock | 4,707 | $0.00 | $0.00 |
DisclosureSEC source: 0001192482-19-000222 · edgar.xml · nonDerivative · entry 1 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,335 F1 · shares: Reflects the grant of restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units vest on April 25, 2020, subject to the director's continued service with the issuer. The restricted stock units will be settled on such date, or, upon the election of the director, on the earlier of the end of the director's service on the Board of Directors, the director's death or disability, or a change in control of the issuer, in shares of the issuer's common stock. Read SEC document |
| March 20, 2019 Filed Mar 22, 2019 20:16 UTC | INSULET CORP PODD · Entity 3516 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $21.35 | $0.00 |
DisclosureSEC source: 0001127602-19-012921 · form4.xml · derivative · entry 3 Fallon John A. · CIK 0001560152 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2022-11-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is subject to a three-year vesting period with 50% of the total award vesting on the first anniversary of the date of grant and 25% of the total award vesting on each of the second and third anniversaries of the date of grant, subject to continued service as a director or consultant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.